NeoStem, Inc. (NBS) in-licensed the Asia rights for Regenrexx, a process that uses a patient?s own mesenchymal stem cells to regenerate joints and bones as an alternative to surgery. After isolating mesenchymal stem cells from bone marrow, the process cultures them for two to three weeks to increase the supply, and then injects them into joints or bones in an office procedure to aid tissue healing and restoration of bone and cartilage.
Terms of the arrangement with Regerative Sciences, the Colorado company that developed Regenerexx, were not disclosed, though the deal was characterized as royalty based.
Christopher Centeno, M.D., founder and CEO of Regnerative Sciences, will become a consultant to NeoStem, Inc. in the area of orthopedic stem cell therapy. He will also train NeoStem personnel in Colorado in mesenchymal stem cell isolation, preparation and transplantation methods.
Regenerative Sciences has not submitted Regenerexx to the FDA for approval, taking the position that regulatory approval is not required for therapeutic use of a patient's own cells as the process does not involve any medical products.
As major benefits, Regenerative Sciences says Regenerexx requires much less recovery time and costs less than surgery.
Regenerexx was the second mesenchymal stem cell in-licensing deal for NeoStem in as many weeks. Last week, NeoStem announced it had acquired worldwide rights for Primcel, a product that aids wound healing. NeoStem closed a capital funding with Asian investors in April and simultaneously announced it would expand its business model from a focus on stem cell storage to include medical tourism in Asia.
Terms of the arrangement with Regerative Sciences, the Colorado company that developed Regenerexx, were not disclosed, though the deal was characterized as royalty based.
Christopher Centeno, M.D., founder and CEO of Regnerative Sciences, will become a consultant to NeoStem, Inc. in the area of orthopedic stem cell therapy. He will also train NeoStem personnel in Colorado in mesenchymal stem cell isolation, preparation and transplantation methods.
Regenerative Sciences has not submitted Regenerexx to the FDA for approval, taking the position that regulatory approval is not required for therapeutic use of a patient's own cells as the process does not involve any medical products.
As major benefits, Regenerative Sciences says Regenerexx requires much less recovery time and costs less than surgery.
Regenerexx was the second mesenchymal stem cell in-licensing deal for NeoStem in as many weeks. Last week, NeoStem announced it had acquired worldwide rights for Primcel, a product that aids wound healing. NeoStem closed a capital funding with Asian investors in April and simultaneously announced it would expand its business model from a focus on stem cell storage to include medical tourism in Asia.